- Home
- DKI vs NCNA Comparison
DKI vs NCNA Comparison
Compare DKI & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DKI | NCNA |
|---|---|---|
| Founded | 2018 | 1997 |
| Country | Hong Kong | United Kingdom |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.7M | 8.8M |
| IPO Year | 2025 | 2017 |
Fundamental Metrics
Financial Performance| Metric | DKI | NCNA |
|---|---|---|
| Price | $0.47 | $2.24 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 11.4M | 66.6K |
| Earning Date | 01-30-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $10,078,798.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 27.25 | N/A |
| 52 Week Low | $0.30 | $2.07 |
| 52 Week High | $15.00 | $268.00 |
Technical Indicators
Market Signals| Indicator | DKI | NCNA |
|---|---|---|
| Relative Strength Index (RSI) | 46.34 | 26.46 |
| Support Level | $0.55 | $2.08 |
| Resistance Level | $0.66 | $2.26 |
| Average True Range (ATR) | 0.10 | 0.19 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 12.23 | 4.72 |
Price Performance
Historical ComparisonAbout DKI DarkIris Inc. Class A Ordinary Shares
Darkiris Inc is a comprehensive technology enterprise engaged in the development, publishing and operating of mobile digital games via various third-party digital storefronts. Its activities encompass including game design, programming and graphics, as well as distribution and operation of mobile games on various platforms. Its core product offerings are Games Development; develop, market and distribute its self-developed mobile games; and Games Publishing and Operation. It publish and operate its self-developed mobile games and mobile games it license from other game developers.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.